Can Mesothelioma Be Treated with Gene Therapy?

Gene Therapy Approaches for Mesothelioma

Gene therapy encompasses a range of experimental strategies that use genetic material to treat or fight cancer. For mesothelioma, several gene therapy approaches are being investigated in preclinical and clinical studies. These include suicide gene therapy, which delivers genes that make cancer cells vulnerable to specific drugs; oncolytic viral therapy, which uses engineered viruses that selectively infect and destroy cancer cells; and immunogene therapy, which introduces genes to enhance the immune response against the tumor.

Mesothelioma is a particularly attractive target for gene therapy research because the tumors are often localized to body cavities (the pleural or peritoneal space), allowing direct delivery of gene therapy agents into the tumor environment via intrapleural or intraperitoneal injection.

Suicide Gene Therapy

One of the most studied gene therapy approaches for mesothelioma is suicide gene therapy, also known as gene-directed enzyme prodrug therapy (GDEPT). In this approach, a modified virus (typically an adenovirus) delivers a gene — most commonly the herpes simplex virus thymidine kinase (HSV-tk) gene — into mesothelioma cells. Once the gene is expressed, the patient receives the antiviral drug ganciclovir, which the HSV-tk enzyme converts into a toxic compound that kills the cancer cell.

A significant advantage of this approach is the “bystander effect” — toxic metabolites produced in treated cells can spread to neighboring untreated cancer cells, amplifying the therapeutic effect beyond the directly infected cells. Clinical trials have demonstrated the safety and feasibility of intrapleural suicide gene therapy, with some patients showing tumor responses.

Oncolytic Viral Therapy

Oncolytic viral therapy uses genetically engineered or naturally occurring viruses that selectively replicate in and destroy cancer cells while leaving normal cells largely unharmed. Several oncolytic viruses have been studied for mesothelioma, including modified adenoviruses, measles vaccine virus, and vesicular stomatitis virus. These viruses can also stimulate an immune response against the tumor, creating a dual mechanism of action.

Early-phase clinical trials have explored intrapleural delivery of oncolytic viruses in combination with chemotherapy or immunotherapy. Results have been promising enough to warrant further investigation in larger trials.

CAR-T Cell Therapy

Chimeric antigen receptor T cell (CAR-T) therapy is a form of immunogene therapy where a patient’s own T cells are genetically modified in the laboratory to express receptors that recognize specific proteins on mesothelioma cells. The engineered T cells are then infused back into the patient, where they seek out and destroy cancer cells bearing the target protein. Mesothelin, a protein highly expressed on mesothelioma cells, is the primary target being studied.

Clinical trials of mesothelin-targeted CAR-T cells for mesothelioma are ongoing at institutions including Memorial Sloan Kettering Cancer Center and the University of Pennsylvania. Early results have shown safety and preliminary evidence of anti-tumor activity.

Accessing Gene Therapy

Gene therapy for mesothelioma is only available through clinical trials. Patients interested in these approaches should discuss eligibility with their oncologist and search for active trials at ClinicalTrials.gov. Specialized mesothelioma treatment centers with research programs are the most likely sites for gene therapy trials. Legal compensation for asbestos exposure may help cover costs associated with travel to and participation in clinical trials.